Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis

Background: Anti-PD-(L)1 antibody monotherapy or in combination with VEGF(R) blockade has been applied widely for cancer treatment. Whether combination therapy increases irAEs still remains controversial.Methods: A systematic review and meta-analysis comparing PD-(L)1 and VEGF(R) blockade combinatio...

Full description

Bibliographic Details
Main Authors: Qiyu Tang, Dawei Wu, Huiyao Huang, Hong Fang, Ying Wu, Funan Liu, Ning Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pharmacology
Subjects:
programmed cell death (ligand) 1
vascular endothelial growth factor (receptor)
immune-related adverse events
treatment-related adverse events
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1093194/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1093194/full

Similar Items